Table 2.

Treatment received and outcomes

	BCL2-DHL	BCL6-DHL	THL	P BCL2-DHL vs. BCL6-DHL	P BCL2-DHL vs. THL	P BCL6-DHL vs. THL
Receipt of IIT	55%	44%	65%	0.42	0.35	0.19
Receipt of CNS prophylaxis	61%	44%	60%	0.27	1.00	0.35
Complete response (CR1)	54%	75%	46%	0.17	0.49	0.10
If receiving IIT	55%	86%	63%	0.22	0.77	0.37
Stem cell transplant (SCT) in CR1	36%	17%	55%	0.30	0.31	0.09
Primary refractory disease	32%	13%	33%	0.14	1.00	0.25
If receiving IIT	25%	14%	14%	1.00	0.71	1.00
Relapse (if responding)	42%	50%	23%	0.75	0.33	0.23
If receiving IIT	36%	33%	25%	0.67	0.29	1.00
Median overall survival (months)	34.8	14.5	17.2	0.89	0.69	0.90
If receiving IIT	37.5	12.1	NYR	0.67	0.91	0.84
If achieving CR1	NYR	14.5	NYR	0.02	0.61	0.10
If relapsing	22.2	11.5	9.7	0.15	0.43	0.82

Abbreviations: IIT, intensive induction therapy (rituximab-EPOCH, rituximab-hyperCVAD, rituximab-CODOX-M/IVAC); NYR, not yet reached; CNS, central nervous system